Stockreport

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of [Read more]